{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:31:48Z","timestamp":1790058708902,"version":"4.0.1"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Summary:<\/jats:title>\n                  <jats:p>Even in diffuse large B-cell lymphoma (DLBCL), a cancer of professional antigen-presenting cells, response rates to immune checkpoint blockade therapy have been limited. One reason for DLBCL immune evasion is epigenetic repression instead of activation of the antigen-presenting MHC\u2014a dissection of mechanisms underlying this repression suggests an opening for restoring B-cell maturation and, along the way, MHC expression as a novel modality of cytoreducing DLBCL and simultaneously augmenting possibilities for immunotherapy.<\/jats:p>\n                  <jats:p>See related article by Ennishi et al., p. 546.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-19-0090","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T12:35:57Z","timestamp":1554122157000},"page":"472-475","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["EZH2 Inhibitors: Take It EZy, It Is All About Context"],"prefix":"10.1158","volume":"9","author":[{"given":"Vamsidhar","family":"Velcheti","sequence":"first","affiliation":[{"name":"1Department of Hematology and Oncology, Langone-Laura and Isaac Perlmutter Cancer Center, New York University, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok-Kin","family":"Wong","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Langone-Laura and Isaac Perlmutter Cancer Center, New York University, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogen","family":"Saunthararajah","sequence":"additional","affiliation":[{"name":"2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio."},{"name":"3Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"2022060701341544800_bib1","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022060701341544800_bib2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2005-04-1510","article-title":"Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions","volume":"107","author":"Rimsza","year":"2006","journal-title":"Blood"},{"key":"2022060701341544800_bib3","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"key":"2022060701341544800_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ccell.2016.07.006","article-title":"EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis","volume":"30","author":"Beguelin","year":"2016","journal-title":"Cancer Cell"},{"key":"2022060701341544800_bib5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1200\/EDBK_199753","article-title":"Ultimate precision: targeting cancer but not normal self-replication","volume":"38","author":"Velcheti","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2022060701341544800_bib6","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1182\/blood-2011-12-391268","article-title":"Polycomb segment myeloid malignancies","volume":"119","author":"Saunthararajah","year":"2012","journal-title":"Blood"},{"key":"2022060701341544800_bib7","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1172\/JCI97117","article-title":"Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates","volume":"128","author":"Gu","year":"2018","journal-title":"J Clin Invest"},{"key":"2022060701341544800_bib8","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-16-0164","article-title":"Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer","volume":"6","author":"Zhang","year":"2016","journal-title":"Cancer Discov"},{"key":"2022060701341544800_bib9","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","article-title":"Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity","volume":"23","author":"Wang","year":"2018","journal-title":"Cell Rep"},{"key":"2022060701341544800_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz013","article-title":"Making immunotherapy \u201ccold\u201d tumours \u201chot\u201d by chemotherapy-induced mutations - a misconception","author":"Helleday","year":"2019  30","journal-title":"Ann Oncol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/9\/4\/472\/1846710\/472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/9\/4\/472\/1846710\/472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T01:37:04Z","timestamp":1654565824000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/9\/4\/472\/10635\/EZH2-Inhibitors-Take-It-EZy-It-Is-All-About"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,1]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-19-0090","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}